Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

FDG PET Imaging For Dementia

치매의 FDG PET 영상

  • Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyungpook National University Medical School and Kyungpook National University Hospital)
  • 안병철 (경북대학교 의과대학 핵의학교실)
  • Published : 2007.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Dementia is a major burden for many countries including South Korea, where life expectancy is continuously growing and the proportion of aged people is rapidly growing. Neurodegenerative disorders, such as, Alzheimer disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson disease, progressive supranuclear palsy, corticobasal degeneration, Huntington disease, can cause dementia, and cerebrovascular disease also can cause dementia. Depression or hypothyroidism also can cause cognitive deficits, but they are reversible by management of underlying cause unlike the forementioned dementias. Therefore these are called pseudodementia. We are entering an era of dementia care that will be based upon the identification of potentially modifiable risk factors and early disease markers, and the application of new drugs postpone progression of dementias or target specific proteins that cause dementia. Efficient pharmacologic treatment of dementia needs not only to distinguish underlying causes of dementia but also to be installed as soon as possible. Therefore, differential diagnosis and early diagnosis of dementia are utmost importance. F-18 FDG PET is useful for clarifying dementing diseases and is also useful for early detection of the diseases. Purpose of this article is to review the current value of FDG PET for dementing diseases including differential diagnosis of dementia and prediction of evolving dementia.

Keywords

References

  1. Grossman H, Bergmann C, Parker S. Dementia: a brief review. Mt Sinai J Med. 2006;73:985-92
  2. Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17:79-89 https://doi.org/10.1007/BF02988444
  3. DH Kim, Epidemiology of dementia in Korea. J Korean Med Assoc 2002;45:356-60 https://doi.org/10.5124/jkma.2002.45.4.356
  4. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465-79 https://doi.org/10.1111/j.1600-0447.1987.tb02906.x
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Forth edition(DSM-IV). Washington, DC : American Psychiatric Association. 1994
  6. Na DL. A clinical approach for patients with dementia. J Korean Med Assoc 2002;45:361-7 https://doi.org/10.5124/jkma.2002.45.4.361
  7. Y Jeong, DL Na. PET studies in Alzheimer disease and other degenerative dementias. Korean J Nucl Med 2003;37:13-23
  8. Saez-Fonseca JA, Lee L, Walker Z. Long-term outcome of depressive pseudodementia in the elderly. 2006 doi:10.1016/j.jad. 2006.11.004
  9. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594-607
  10. MY Park. Differential diagnosis of vascular dementia and Alzheimer disease. J Korean Med Assoc 2002;45:392-400 https://doi.org/10.5124/jkma.2002.45.4.392
  11. Metter EJ, Mazziotta JC, Itabashi HH, Mankovich NJ, Phelps ME, Kuhl DE. Comparison of glucose metabolism, x-ray CT, and postmortem data in a patient with multiple cerebral infarcts. Neurology 1985;35:1695-701 https://doi.org/10.1212/WNL.35.12.1695
  12. Tedeschi E, Hasselbalch SG, Waldemar G, Juhler M, Hogh P, Holm S, Garde L, et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 1995;59:608-15 https://doi.org/10.1136/jnnp.59.6.608
  13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
  14. Alzheimer A. Uber eine eigenartige Erkrangkung der Hirnrinde, Allg Zeitschr Psychiatr Psychiatr-Gerichtl Med 1907;146-8
  15. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993;43:13-20 https://doi.org/10.1212/WNL.43.1_Part_1.13
  16. Stern Y, Alexander GE, Prohovnik I, Stricks L, Link B, Lennon MC, Mayeux R. Relationship between lifetime occupation and parietal flow: implications for reserve against Alzheimer's disease pathology. Neurology 1995;45:55-60 https://doi.org/10.1212/WNL.45.1.55
  17. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer's disease: a look to the future. Radiology 2003;226:315-36 https://doi.org/10.1148/radiol.2262011600
  18. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging 2005;32:486-510 https://doi.org/10.1007/s00259-005-1762-7
  19. St George-Hyslop P. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000;47:183-99 https://doi.org/10.1016/S0006-3223(99)00301-7
  20. Tanzi R, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181-4 https://doi.org/10.1016/S0896-6273(01)00476-7
  21. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006;66(Suppl 1):S79-S85 https://doi.org/10.1212/01.wnl.0000192102.41141.9e
  22. Friedland RP, Fritsch T, Smyth KA, Koss E, Lerner AJ, Chen CH, Petot GJ, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A 2001;98:3440-5 https://doi.org/10.1073/pnas.061002998
  23. Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003;8:815-23 https://doi.org/10.1017/S1092852900019258
  24. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63:530-8 https://doi.org/10.1001/archpsyc.63.5.530
  25. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006;63:161-7 https://doi.org/10.1001/archpsyc.63.2.161
  26. Coleman RE. Positron emission tomography diagnosis of Alzheimer's disease. Neuroimag Clin N Am 2005;15:837-46 https://doi.org/10.1016/j.nic.2005.09.007
  27. Mayeux R, Sano M. Treatment of Alzheimer disease. New Engl J Med 2000;341:1670-9 https://doi.org/10.1056/NEJM199911253412207
  28. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53 https://doi.org/10.1212/WNL.56.9.1143
  29. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, et al. Comparison of different MRI brain atrophy measures with clinical disease progression in AD. Neurology 2004;62:591-600 https://doi.org/10.1212/01.WNL.0000110315.26026.EF
  30. Minoshima S, Giordani B, Berent S. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94 https://doi.org/10.1002/ana.410420114
  31. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P , et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16 https://doi.org/10.1006/nimg.2002.1208
  32. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92 https://doi.org/10.1001/archneur.58.12.1985
  33. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-42 https://doi.org/10.1212/WNL.56.9.1133
  34. Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, Halber M, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:494-504 https://doi.org/10.1159/000017196
  35. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, Satyamurthy N, Barrio JR. 2-dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 2003;5: 404-17 https://doi.org/10.1016/j.mibio.2003.09.010
  36. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388: 839-40 https://doi.org/10.1038/42166
  37. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-6 https://doi.org/10.1212/WNL.47.2.462
  38. Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, Shimomura T, Hashimoto M, Tanimukai S, Kazui H, Mori E. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci. Lett. 1997;235:49-52 https://doi.org/10.1016/S0304-3940(97)00713-1
  39. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-65 https://doi.org/10.1002/ana.1133
  40. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for severity. J Nucl Med 1997;38:797-802
  41. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, Persad C, et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005;191(Suppl 1):S95-S103 https://doi.org/10.1016/j.expneurol.2004.06.017
  42. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. 2002;73:134-40 https://doi.org/10.1136/jnnp.73.2.134
  43. Knibb JA, Kipps CM, Hodges JR. Frontotemporal dementia. Curr Opin Neurol 2006;19:565-71 https://doi.org/10.1097/01.wco.0000247606.57567.41
  44. Gustafson L. Frontal lobe degeneration of non-Alzheimer type. II. Clinical picture and differential diagnosis. Arch Gerontol Geriatr 1987;6:209-23 https://doi.org/10.1016/0167-4943(87)90022-7
  45. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003;49:13-9 https://doi.org/10.1159/000067021
  46. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17:355-9 https://doi.org/10.1159/000077171
  47. Hodges JR, Warlow CP. The etiology of transient global amnesia: a case-control study of 114 cases with prospective follow-up. Brain 1990;113:639-58 https://doi.org/10.1093/brain/113.3.639
  48. Josephs KA, Knopman DS, Whitwell JL, Boeve BF, Parisi JE, Petersen RC, Dickson DW. Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs. FTLD-MND. Neurology 2005;65:645-7 https://doi.org/10.1212/01.wnl.0000173178.67986.7f
  49. Ferreri F, Agbokou C, Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ 2006;175:1545-52 https://doi.org/10.1503/cmaj.060542
  50. Galvin JE. Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 2006;20:302-10 https://doi.org/10.1097/01.wad.0000213858.27731.f8
  51. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogenous degeneration involving the brain stem, basal gangliaand cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia dementia. Arch Neurol 1964;10:333-59 https://doi.org/10.1001/archneur.1964.00460160003001
  52. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 1988;24: 399-406 https://doi.org/10.1002/ana.410240308
  53. Litvan I. Cognitive disturbances in progressive supranuclear palsy. J Neural Transm 1994;42:69-78
  54. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994;117:1183-96 https://doi.org/10.1093/brain/117.5.1183
  55. Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, Lewington G, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186:17-20 https://doi.org/10.1016/0304-3940(95)11270-7
  56. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-83 https://doi.org/10.1016/0092-8674(93)90585-E
  57. Geser F, Wenning GK. The diagnosis of multiple system atrophy. J Neurol 2006;253(Suppl 3):iii2-iii15 https://doi.org/10.1007/s00415-006-3002-x
  58. Quinn NP. How to diagnose multiple system atrophy. Mov Disord 2005;20(Suppl 12):S5-S10 https://doi.org/10.1002/mds.20534
  59. Gilman S, Low PA,Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ,Kaufmann H,Klockgether T, Lang AE, Lantos PL, Litvan I,Mathias CJ,Oliver E, Robertson D, Schatz I,Wenning GK. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189-92
  60. Park J, Ko HJ, Park YN, Jung CH. Dementia among the elderly in a, rural Korean community. British J Psychiat 1994;167:796-801
  61. Woo JI, Lee JH, Yoo KY, Kim CY, Kim YI, Shin YS. Prevalence estimation of dementia in a rural area of Korea. J Am Geriatr Soc 1998;46:983-7 https://doi.org/10.1111/j.1532-5415.1998.tb02753.x
  62. Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S10-S15
  63. Looi JC, Sachdev PS. Differentiation of vascular dementia from Alzheimer's disease on neuropsychological tests. Neurology 1999;53:670-8 https://doi.org/10.1212/WNL.53.4.670
  64. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60 https://doi.org/10.1212/WNL.43.2.250
  65. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23-30
  66. Jellinger KA. The enigma of mixed dementia. Alzheimer's and dementia 2007;3:40-53 https://doi.org/10.1016/j.jalz.2006.09.002
  67. Rockwood K, Bowler J, Erkinjuntti T, Hachinski V, Wallin A. Subtypes of vascular dementia. Alzheimer Dis Assoc Disord 1999;13(Suppl 3):S59-65 https://doi.org/10.1097/00002093-199912003-00010
  68. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002;109:813-36 https://doi.org/10.1007/s007020200068
  69. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke 2004; 35(11 Suppl 1):2616-9 https://doi.org/10.1161/01.STR.0000143224.36527.44
  70. Haglund M, Sjobeck M, Englund E. Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord 2004;18:132-7 https://doi.org/10.1159/000079192
  71. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277(10):813-7
  72. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000;21:321-30 https://doi.org/10.1016/S0197-4580(00)00125-1
  73. Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol Scand 2006;114:38-46 https://doi.org/10.1111/j.1600-0404.2006.00665.x
  74. Zanni GR, Wick JY. Differentiating dementias in long-term care patients. Consult Pharm 2007;22:14-6, 18, 21-8 https://doi.org/10.4140/TCP.n.2007.14
  75. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999;156:675-82
  76. Hirono N, Mori E, Ishii K, Ikejiri Y, Imamura T, Shimomura T, et al. Frontal lobe hypometabolism and depression in Alzheimer's disease. Neurology 1998;50:380-3 https://doi.org/10.1212/WNL.50.2.380
  77. Guze BH, Baxter LR, Schwartz JM, Szuba MP, Mazziotta JC, Phelps ME. Changes in glucose metabolism in dementia of the Alzheimer type compared with depression: a preliminary report. Psychiatry Res 1991;40:195-202 https://doi.org/10.1016/0165-1781(91)90158-L
  78. Mayberg HS. Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin N Am 2003; 13:805-15 https://doi.org/10.1016/S1052-5149(03)00104-7
  79. Whybrow PC 1996 Behavioral and psychiatric aspects of hypothyroidism. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The thyroid, ed 7. Philadelphia: Lippincott-Raven; 866-9
  80. Constant EL, de Volder AG, Ivanoiu A, Bol A, Labar D, Seghers A, Cosnard G, Melin J, Daumerie C. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. J Clin Endocrinol Metab 2001;86:3864-70 https://doi.org/10.1210/jc.86.8.3864